Silencing TCF4 Sensitizes Melanoma Cells to Vemurafenib Through Inhibiting GLUT3-Mediated Glycolysis

BACKGROUND: Vemurafenib is a selective BRAF inhibitor with significant early effects in melanoma, but resistance will develop with the duration of treatment. Therefore, overcoming vemurafenib resistance can effectively improve the survival rate of melanoma. The transcriptional activity of TCF4 is ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Can, He, Siqi, Zhang, Jianfei, Li, Shiyan, Chen, Jian, Han, Chaofei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269014/
https://www.ncbi.nlm.nih.gov/pubmed/32581551
http://dx.doi.org/10.2147/OTT.S245531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269014/
https://www.ncbi.nlm.nih.gov/pubmed/32581551
http://dx.doi.org/10.2147/OTT.S245531

Ejemplares similares